These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33651460)

  • 1. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
    Gomez-Peralta F; Al-Ozairi E; Jude EB; Li X; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1445-1452. PubMed ID: 33651460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
    Mehta R; Billings LK; Liebl A; Vilsbøll T
    Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
    McCrimmon RJ; Al Sifri S; Emral R; Mohan V; Sauque-Reyna L; Trescolí C; Lalic N; Alvarez A; Demil N; Coudert M; Shaunik A; Bonnemaire M; Rosenstock J;
    Diabetes Obes Metab; 2021 Jun; 23(6):1221-1231. PubMed ID: 33606908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
    Perreault L; Rodbard H; Valentine V; Johnson E
    Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
    Kaneto H; Koshida R; Baxter M
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():24-34. PubMed ID: 32436323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
    Lisco G; De Tullio A; Guastamacchia E; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
    Home P; Blonde L; Kalra S; Ji L; Guyot P; Brulle-Wohlhueter C; Murray E; Shah R; Sayre T; Shaunik A
    Diabetes Obes Metab; 2020 Nov; 22(11):2179-2188. PubMed ID: 32700442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
    Wysham CH; Lin J; Kuritzky L
    Postgrad Med; 2017 May; 129(4):436-445. PubMed ID: 28294702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
    Blonde L; Anderson JE; Chava P; Dendy JA
    Curr Med Res Opin; 2019 May; 35(5):793-804. PubMed ID: 30370783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
    Carris NW; Taylor JR; Gums JG
    Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
    Trautmann ME; Vora J
    Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Validation Survey to Assess Usage of Premix Insulins in Management of Diabetes with Respect to the Recommendations Enlisted in Indian Guidelines.
    Kalra S; Sahay R; Tiwaskar M; Priya G; Das S; Bantwal G
    J Assoc Physicians India; 2020 Jun; 68(6):20-25. PubMed ID: 32610874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.
    Bostandzic AD; Beslic VK; Surkovic I; Balic S; Dujic T; Asimi ZV; Burekovic A
    Med Arch; 2022 Apr; 76(2):96-100. PubMed ID: 35774039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
    Novodvorský P; Haluzík M
    Expert Opin Drug Saf; 2022 Mar; 21(3):349-361. PubMed ID: 34641742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.